UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant  ☒                            Filed by a party other than the Registrant  ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-12

Anika Therapeutics, Inc.

(Name of Registrant as Specified in its Charter)

Not applicable.

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒	No fee required.
☐	Fee paid previously with preliminary materials.
☐	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

Your Vote Counts!ANIKA THERAPEUTICS, INC.2023 Annual MeetingVote by June 13, 2023 11:59 PM ET.ANIKA THERAPEUTICS, INC. ATTN: DAVID COLLERAN32 WIGGINS AVE.BEDFORD, MA 01730V16964-P94816You invested in ANIKA THERAPEUTICS, INC. and its time to vote!You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on June 14, 2023.Get informed before you voteView the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 31, 2023. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.For complete information and to vote, visit www.ProxyVote.com Control #Smartphone usersPoint your camera here and vote without entering a control numberVote Virtually at the Meeting*June 14, 20239:00 a.m., Eastern TimeVirtually at: www.virtualshareholdermeeting.com/ANIK2023*Please check the meeting materials for any special requirements for meeting attendance.V1.2

Vote at www.ProxyVote.comTHIS IS NOT A VOTABLE BALLOTThis is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.Voting Items Board Recommends1. Election of three Class III Directors Nominees:1a. Gary P. Fischetti For 1b. John B. Henneman, III For 1c. Susan L.N. Vogt For2. Ratification of Deloitte & Touche LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2023. ForFor ending December 31, 2023.3. Advisory vote on the compensation of the Companys named executive officers. For4. Advisory vote on the frequency of future advisory votes on executive compensation. 1 Year5. Approval of the Amendment to the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof.Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click Delivery Settings.V16965-P94816